These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 9056020

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.
    Pong A, Thomson KS, Moland ES, Chartrand SA, Sanders CC.
    J Antimicrob Chemother; 1999 Nov; 44(5):621-7. PubMed ID: 10552978
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin.
    Klugman KP, Capper T.
    J Antimicrob Chemother; 1997 Dec; 40(6):797-802. PubMed ID: 9462430
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. In vitro activities of DX-619 and four comparator agents against 376 anaerobic bacterial isolates.
    Molitoris D, Väisänen ML, Bolaños M, Finegold SM.
    Antimicrob Agents Chemother; 2006 May; 50(5):1887-9. PubMed ID: 16641470
    [Abstract] [Full Text] [Related]

  • 28. Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates.
    Hecht DW, Osmolski JR.
    Antimicrob Agents Chemother; 2003 Mar; 47(3):910-6. PubMed ID: 12604521
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to BAY 12-8039, trovafloxacin, and ciprofloxacin.
    Hoppe JE, Dalhoff A, Pfründer D.
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1868. PubMed ID: 9661039
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms.
    Ednie LM, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2459-62. PubMed ID: 9736586
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Minimal inhibitory concentrations and time-kill determination of moxifloxacin against aerobic and anaerobic isolates.
    Speciale A, Musumeci R, Blandino G, Milazzo I, Caccamo F, Nicoletti G.
    Int J Antimicrob Agents; 2002 Feb; 19(2):111-8. PubMed ID: 11850163
    [Abstract] [Full Text] [Related]

  • 38. Quinolone activity against anaerobes: microbiological aspects.
    Appelbaum PC.
    Drugs; 1995 Feb; 49 Suppl 2():76-80. PubMed ID: 8549420
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
    Dalhoff A, Petersen U, Endermann R.
    Chemotherapy; 1996 Feb; 42(6):410-25. PubMed ID: 8957575
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.